Revvity Inc experiences decline amid healthcare sector weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 29 2025
0mins
Should l Buy RVTY?
Source: Coinmarketcap
Revvity Inc's stock price fell by 4.0% as it crossed below the 5-day SMA, reflecting the broader struggles within the healthcare sector.
The healthcare sector is down 1.8%, with Revvity Inc among the underperformers, indicating overall weakness that may affect investor confidence. This decline is compounded by a lack of investor confidence in the financial sector, which is also down 1.8%, contributing to a cautious market sentiment.
The ongoing weakness in both the healthcare and financial sectors suggests potential challenges for Revvity Inc, as investor sentiment remains cautious, leading to possible capital outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 90.300
Low
105.00
Averages
113.38
High
123.00
Current: 90.300
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare and Financial Sectors Underperforming
- Healthcare Sector Decline: As of midday Friday, the healthcare sector is down 1.8%, with CRH plc and Revvity Inc showing losses of 4.3% and 4.0%, respectively, indicating overall weakness that may affect investor confidence.
- ETF Underperformance: The Health Care Select Sector SPDR ETF is down 1.1% on the day and 1.63% year-to-date, reflecting a cautious investor sentiment towards the healthcare sector, potentially leading to capital outflows.
- Financial Sector Weakness: The financial sector is also down 1.8%, with Blackrock Inc and Ares Management Corp declining by 7.4% and 6.6%, respectively, signaling market concerns over financial stocks that could impact overall market sentiment.
- ETF Tracking Financial Stocks: The Financial Select Sector SPDR ETF is down 2.0% in midday trading and 8.30% year-to-date, indicating a lack of investor confidence in the financial sector, which may lead to broader market volatility.
See More
Bretton Fund Q4 2025 Performance Analysis
- Quarterly Performance: The Bretton Fund achieved a return of 1.44% in Q4 2025, lagging behind the S&P 500's 2.66% gain, indicating a potential disadvantage in market competitiveness that may affect investor confidence.
- Portfolio Adjustments: In Q4 2025, the fund exited its positions in Union Pacific (UNP) and Revvity (RVTY), suggesting a strategic shift in response to changing market conditions that could impact future earnings potential.
- Market Comparison: The fund's performance trailing the S&P 500 reflects a need for reevaluation of its investment strategy to maintain competitiveness amid future market fluctuations.
- Industry Dynamics: Union Pacific's presentation at Barclays' 43rd Annual Industrial Select Conference highlights ongoing interest in the company, which may influence the Bretton Fund's investment decisions moving forward.
See More
Revvity Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Revvity reported Q4 2025 adjusted earnings of $1.70 per share, a 19.7% year-over-year increase, surpassing the consensus estimate of $1.55, indicating strong performance in the life sciences and diagnostics sector.
- Sales Growth: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting robust market demand.
- Positive Outlook: Revvity forecasts fiscal 2026 adjusted earnings between $5.35 and $5.45 per share, above the consensus of $5.32, demonstrating confidence in future growth prospects.
- Sales Guidance: The company anticipates fiscal 2026 sales between $2.96 billion and $2.99 billion, higher than the consensus of $2.93 billion, indicating a year-over-year growth of 4%-5% and organic growth of 2%-3%.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, indicating a divergence in market sentiment regarding the company's future prospects, which could influence investor decisions and market mood.
- Market Reaction Monitoring: While specific rating changes were not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor subsequent market developments.
- Impact of Rating Changes: Upgrades or downgrades from analysts can lead to short-term volatility in ROKU's stock, making it essential for investors to consider these rating changes in their investment strategies.
- Investor Recommendations: When considering the purchase of ROKU stock, investors are advised to reference the latest analyst ratings and market trends to make more informed investment decisions.
See More
Revvity Q4 2025 Earnings Exceed Expectations
- Strong Financial Performance: Revvity reported $772 million in revenue for Q4 2025, reflecting a 4% year-over-year growth, with Diagnostics revenue reaching $390 million, up 10%, showcasing the company's resilience and growth potential in a challenging environment.
- Adjusted EPS Exceeds Expectations: The company achieved an adjusted EPS of $1.70, surpassing market expectations, with a full-year adjusted EPS of $5.06, indicating effective management strategies in response to adverse policy conditions.
- Robust Future Outlook: Management projects organic growth for 2026 to be in the range of 2% to 3%, with total expected revenue between $2.96 billion and $2.99 billion, reflecting a cautiously optimistic view on market recovery while emphasizing disciplined capital allocation.
- Strategic Investments and Innovations: Revvity announced the acquisition of ACD/Labs software and the launch of the AI models as a service platform Signals Xynthetica, which are expected to drive future revenue growth and enhance market competitiveness through collaboration with Lilly's TuneLab.
See More
Revvity Reports Q4 and FY 2025 Results, Shares Decline
- Earnings Report Reaction: Revvity's release of its Q4 and FY 2025 financial results led to a 5.07% drop in shares to $103.28, indicating market concerns over profitability and cost dynamics despite adjusted earnings growth.
- Strong Market Reaction: On the announcement day, Revvity's stock opened near $109, dipped to an intraday low of $102, and trading volume surpassed average levels, reflecting strong investor reactions to the earnings and guidance.
- Uneven Business Performance: While the company reported solid revenue and adjusted earnings, the market remained cautious due to uneven performance across business segments and margin pressure, contributing to a bearish sentiment.
- Cautious 2026 Outlook: Revvity's guidance for 2026 indicates continued growth but fails to fully alleviate market concerns regarding cost dynamics and profitability trends, leading to increased selling pressure.
See More
Healthcare and Financial Sectors Underperforming
- Healthcare Sector Decline: As of midday Friday, the healthcare sector is down 1.8%, with CRH plc and Revvity Inc showing losses of 4.3% and 4.0%, respectively, indicating overall weakness that may affect investor confidence.
- ETF Underperformance: The Health Care Select Sector SPDR ETF is down 1.1% on the day and 1.63% year-to-date, reflecting a cautious investor sentiment towards the healthcare sector, potentially leading to capital outflows.
- Financial Sector Weakness: The financial sector is also down 1.8%, with Blackrock Inc and Ares Management Corp declining by 7.4% and 6.6%, respectively, signaling market concerns over financial stocks that could impact overall market sentiment.
- ETF Tracking Financial Stocks: The Financial Select Sector SPDR ETF is down 2.0% in midday trading and 8.30% year-to-date, indicating a lack of investor confidence in the financial sector, which may lead to broader market volatility.
See More
Bretton Fund Q4 2025 Performance Analysis
- Quarterly Performance: The Bretton Fund achieved a return of 1.44% in Q4 2025, lagging behind the S&P 500's 2.66% gain, indicating a potential disadvantage in market competitiveness that may affect investor confidence.
- Portfolio Adjustments: In Q4 2025, the fund exited its positions in Union Pacific (UNP) and Revvity (RVTY), suggesting a strategic shift in response to changing market conditions that could impact future earnings potential.
- Market Comparison: The fund's performance trailing the S&P 500 reflects a need for reevaluation of its investment strategy to maintain competitiveness amid future market fluctuations.
- Industry Dynamics: Union Pacific's presentation at Barclays' 43rd Annual Industrial Select Conference highlights ongoing interest in the company, which may influence the Bretton Fund's investment decisions moving forward.
See More
Revvity Reports Strong Q4 Earnings, Beats Expectations
- Earnings Beat: Revvity reported Q4 2025 adjusted earnings of $1.70 per share, a 19.7% year-over-year increase, surpassing the consensus estimate of $1.55, indicating strong performance in the life sciences and diagnostics sector.
- Sales Growth: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting robust market demand.
- Positive Outlook: Revvity forecasts fiscal 2026 adjusted earnings between $5.35 and $5.45 per share, above the consensus of $5.32, demonstrating confidence in future growth prospects.
- Sales Guidance: The company anticipates fiscal 2026 sales between $2.96 billion and $2.99 billion, higher than the consensus of $2.93 billion, indicating a year-over-year growth of 4%-5% and organic growth of 2%-3%.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, indicating a divergence in market sentiment regarding the company's future prospects, which could influence investor decisions and market mood.
- Market Reaction Monitoring: While specific rating changes were not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor subsequent market developments.
- Impact of Rating Changes: Upgrades or downgrades from analysts can lead to short-term volatility in ROKU's stock, making it essential for investors to consider these rating changes in their investment strategies.
- Investor Recommendations: When considering the purchase of ROKU stock, investors are advised to reference the latest analyst ratings and market trends to make more informed investment decisions.
See More
Revvity Q4 2025 Earnings Exceed Expectations
- Strong Financial Performance: Revvity reported $772 million in revenue for Q4 2025, reflecting a 4% year-over-year growth, with Diagnostics revenue reaching $390 million, up 10%, showcasing the company's resilience and growth potential in a challenging environment.
- Adjusted EPS Exceeds Expectations: The company achieved an adjusted EPS of $1.70, surpassing market expectations, with a full-year adjusted EPS of $5.06, indicating effective management strategies in response to adverse policy conditions.
- Robust Future Outlook: Management projects organic growth for 2026 to be in the range of 2% to 3%, with total expected revenue between $2.96 billion and $2.99 billion, reflecting a cautiously optimistic view on market recovery while emphasizing disciplined capital allocation.
- Strategic Investments and Innovations: Revvity announced the acquisition of ACD/Labs software and the launch of the AI models as a service platform Signals Xynthetica, which are expected to drive future revenue growth and enhance market competitiveness through collaboration with Lilly's TuneLab.
See More
Revvity Reports Q4 and FY 2025 Results, Shares Decline
- Earnings Report Reaction: Revvity's release of its Q4 and FY 2025 financial results led to a 5.07% drop in shares to $103.28, indicating market concerns over profitability and cost dynamics despite adjusted earnings growth.
- Strong Market Reaction: On the announcement day, Revvity's stock opened near $109, dipped to an intraday low of $102, and trading volume surpassed average levels, reflecting strong investor reactions to the earnings and guidance.
- Uneven Business Performance: While the company reported solid revenue and adjusted earnings, the market remained cautious due to uneven performance across business segments and margin pressure, contributing to a bearish sentiment.
- Cautious 2026 Outlook: Revvity's guidance for 2026 indicates continued growth but fails to fully alleviate market concerns regarding cost dynamics and profitability trends, leading to increased selling pressure.
See More
